Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Blood (2023) 142 (18): 1570–1575.

https://doi.org/10.1182/blood.2023021212

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis

P. Martijn Kolijn, Florentin Späth, Mouhamad Khouja, Paul J. Hengeveld, Lina van der Straten, Nikos Darzentas, Magnus Hultdin, James D. McKay, Christiane Pott, Roel C. H. Vermeulen, Anton W. Langerak

Blood (2023) 142 (16): 1399–1403.

https://doi.org/10.1182/blood.2023019609

Published: 2023

Includes: Supplemental data

Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Blood (2023) 142 (13): 1131–1142.

https://doi.org/10.1182/blood.2023020195

Published: 2023

Includes: Supplemental data

Journal Articles

Detecting measurable residual disease beyond 10 −4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Paul J. Hengeveld, Michèle Y. van der Klift, P. Martijn Kolijn, Frédéric Davi, François G. Kavelaars, Evert de Jonge, Sandra Robrecht, Jorn L. J. C. Assmann, Lina van der Straten, Matthias Ritgen, Peter E. Westerweel, Kirsten Fischer, Valentin Goede, Michael Hallek, Mark-David Levin, Anton W. Langerak

Blood (2023) 141 (5): 519–528.

https://doi.org/10.1182/blood.2022017411

Published: 2023

Includes: Supplemental data

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

Blood (2022) 140 (Supplement 1): 1800–1802.

https://doi.org/10.1182/blood-2022-165181

Published: 2022

Journal Articles

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul Hengeveld, Pieter M. Kolijn, Jeroen A.A. Demmers, Wouter Doff, Julie M.N. Dubois, Melissa Rijken, Jorn Assmann, Lina Van Der Straten, Henk-Jan Boiten, Kirsten J. Gussinklo, Peter J.M. Valk, Peter E. Westerweel, Arnon P. Kater, Anton W. Langerak, Mark-David Levin

Blood (2022) 140 (Supplement 1): 9851–9852.

https://doi.org/10.1182/blood-2022-158881

Published: 2022

Journal Articles

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis

Blood (2022) 139 (10): 1557–1563.

https://doi.org/10.1182/blood.2021012890

Published: 2022

Includes: Supplemental data

Journal Articles

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H.J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2021) 138 (Supplement 1): 1314.

https://doi.org/10.1182/blood-2021-152971

Published: 2021

Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2021-147731

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Arnon P. Kater, Tong Lu, Anton W. Langerak, Clemens Mellink, Brenda Chyla, Jenny Qun Wu, Michelle Boyer, Marcus Lefebure, Yanwen Jiang, John F. Seymour

Blood (2021) 138 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2021-148612

Published: 2021

Journal Articles

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider, Lone Bredo Pedersen, Renee C. Tschumper, Lesley-Ann Sutton, Panagiotis Baliakas, Lydia Scarfò, Ellen J. van Gastel, Marine Armand, Eugen Tausch, Bella Biderman, Constance Baer, Davide Bagnara, Alba Navarro, Anne Langlois de Septenville, Valentina Guido, Gerlinde Mitterbauer-Hohendanner, Aleksandar Dimovski, Christian Brieghel, Sarah Lawless, Manja Meggendorfer, Kamila Brazdilova, Matthias Ritgen, Monica Facco, Cristina Tresoldi, Andrea Visentin, Andrea Patriarca, Mark Catherwood, Lisa Bonello, Andrey Sudarikov, Katrina Vanura, Maria Roumelioti, Hana Skuhrova Francova, Theodoros Moysiadis, Silvio Veronese, Krzysztof Giannopoulos, Larry Mansouri, Teodora Karan-Djurasevic, Raphael Sandaltzopoulos, Csaba Bödör, Franco Fais, Arnon Kater, Irina Panovska, Davide Rossi, Salem Alshemmari, Panagiotis Panagiotidis, Paul Costeas, Blanca Espinet, Darko Antic, Letizia Foroni, Marco Montillo, Livio Trentin, Niki Stavroyianni, Gianluca Gaidano, Paola Francia di Celle, Carsten Niemann, Elias Campo, Achilles Anagnostopoulos, Christiane Pott, Kirsten Fischer, Michael Hallek, David Oscier, Stephan Stilgenbauer, Claudia Haferlach, Diane Jelinek, Nicholas Chiorazzi, Sarka Pospisilova, Marie-Paule Lefranc, Sofia Kossida, Anton W. Langerak, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 137 (10): 1365–1376.

https://doi.org/10.1182/blood.2020007039

Published: 2021

Includes: Supplemental data

Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Blood (2019) 134 (Supplement_1): 36.

https://doi.org/10.1182/blood-2019-125825

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Blood (2019) 134 (Supplement_1): 888.

https://doi.org/10.1182/blood-2019-127822

Published: 2019

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 185.

https://doi.org/10.1182/blood-2018-99-117050

Published: 2018

Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

Blood (2018) 131 (9): 955–962.

https://doi.org/10.1182/blood-2017-06-792333

Published: 2018

Includes: Supplemental data

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Sven Estenfelder, MD, Ann-Kathrin Holland-Letz, Eugen Tausch, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1738.

https://doi.org/10.1182/blood.V130.Suppl_1.1738.1738

Published: 2017

NARROW

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Detecting measurable residual disease beyond 10 −4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only